Asset 1-Jul-06-2023-09-31-57-4180-AM-1-1-1

AVAILABLE FOR PRE-ORDER ONLY

MERCURIUS™

Total DRUG-seq kits

Ultra-scalable, extraction-free total RNA-seq for transcriptomic profiling and target discovery

Compatible with Illumina®, AVITI™ and MGI*.

* For native kits' compatibility with MGI sequencers, contact us.


Catalog number	#10705	#11661	#10706	#11662
Total preps How many library preps can be prepared in total with one kit	96	384	384	1'536
Sample multiplexing and plate format How many samples can be multiplexed in one single tube	96	96	384	384
Barcoded oligo-dT plates included	1	4	1	4
UDI pairs included How many individual libraries can be sequenced together	4	4	4	4
Documentation	User guide Barcode files

Cat ##10705
Total reactions How many library preps can be prepared in total with one kit	96
RNA multiplexing format How many library preps can be prepared in total with one kit	96
UDI pairs included How many library preps can be prepared in total with one kit	4
Download Manual

Cat ##11661
Total reactions How many library preps can be prepared in total with one kit	384
RNA multiplexing format How many library preps can be prepared in total with one kit	96
UDI pairs included How many library preps can be prepared in total with one kit	4
Download Manual

Cat ##10706
Total reactions How many library preps can be prepared in total with one kit	384
RNA multiplexing format How many library preps can be prepared in total with one kit	384
UDI pairs included How many library preps can be prepared in total with one kit	4
Download Manual

Cat ##11662
Total reactions How many library preps can be prepared in total with one kit
RNA multiplexing format How many library preps can be prepared in total with one kit	384
UDI pairs included How many library preps can be prepared in total with one kit	4
Download Manual

Benefits

Ideal for transcriptomic profiling and target validation: Robust results empower faster, data-rich decision-making in the drug discovery pipeline.

Multiplexed full-length RNA: Full-length RNA-seq library prep, 96 or 384 samples in a single tube. For both coding and non-coding RNAs.

Full-length transcript coverage: From differential gene expression to transcript variants, alternative splicing, or fusion genes.

No prior RNA extraction: An optimized lysis buffer for complete lysis and efficient reverse transcription.

Improved protocol: Without pre-amplification, leading to higher mapping and gene detection rates.

One-day lab workflow: Convenient and short protocol from samples to sequencing-ready libraries in one day.

Experimental workflow at a glance
Performance
Product specifications
Validated cell lines

Total DRUG-seq-1

1. Total DRUG-seq has a high demultiplexing rate and the majority of reads map to exons or the genome

Total DRUG-seq library performance sequenced at 5.6 million reads per sample.

2. Total DRUG-seq exhibits reads distribution across the transcript’s entire length

The gene body coverage shows a consistent and uniform reads distribution across the entire gene body for the Total DRUG-seq protocol, comparable to the competitor N protocol, while the 3' DRUG-seq protocol shows a significant 3' bias due to its poly-A selection methodology.

3. Total DRUG-seq exhibits an improved protocol for transcript detection

The MERCURIUS™ Total DRUG-seq features an improved protocol that enables more comprehensive transcript detection compared to the 3' DRUG-seq approach, delivering deeper insights for compound screening and target validation.

4. Identification of alternative promoter usage with Total DRUG-seq

MERCURIUS™ Total DRUG-seq reveals differential promoter usage in response to TGFB treatment: HNF4A promoter 1 (P1)is inhibited, while promoter 2 (P2) is activated. This switch in promoter activity is a hallmark of epithelial-to-mesenchymal transition and is associated with tumor progression. Activation of HNF4A P2 is a known marker of hepatocarcinoma progression, highlighting the power of Total DRUG-seq to resolve complex transcriptional regulation at the promoter level.

For (application)	Full-length RNA sequencing
For use with (equipment)	Illumina and AVITI or MGI instruments
Species compatibility	All eukaryotic species
Available formats	96 and 384 preps
Shipping conditions	Dry ice
Storage conditions	-20C

Cell line/Tissue	Organism
HT1080 SMARCA4 KO	Human
hTEC	Human
iPSC microglia	Human
MCF7	Human
HepG2_IGF1RKO	Human
Beas-2B	Human
dTHP-1	Human
iPSC derived cardiomyocytes	Human
Endothelial	Human
Hepatocyte	Human
HEPG2	Human
Hepatocyte	Human
SF9	Spodoptera
A549	Human
Breast Cancer (MCF7)	Human
B lymphoblast MM.1s.	Human
Hek293	Human
HeLa Cells	Human
U2-OS	Human
Hek293	Human
dTHP-1	Human
AsPC-1	Human
PBMC (TCD4)	Human
Skeletal muscle (LHCN-M2)	Human
HepaRG	Human
Macrophage (MV-4-11)	Human
PBMCs (Blood)	Human
Microglia	Human
Fibroblast Like Synoviocyte donor 1502	Human
Fibroblast	Human
iPSC-derived neuron	Human
Human lung carcinoma epithelial cell line	Human
Human breast epithelial adenocarcinoma cell line	Human
Human liver hepatocellular carcinoma cell line	Human
Human cardiomyocytes derived from induced pluripotent stem cells (iPSCs)	Human

1. Total DRUG-seq has a high demultiplexing rate and the majority of reads map to exons or the genome

Total DRUG-seq library performance sequenced at 5.6 million reads per sample.

2. Total DRUG-seq exhibits reads distribution across the transcript’s entire length

The gene body coverage shows a consistent and uniform reads distribution across the entire gene body for the Total DRUG-seq protocol, comparable to the competitor N protocol, while the 3' DRUG-seq protocol shows a significant 3' bias due to its poly-A selection methodology.

3. Total DRUG-seq exhibits an improved protocol for transcript detection

The MERCURIUS™ Total DRUG-seq features an improved protocol that enables more comprehensive transcript detection compared to the 3' DRUG-seq approach, delivering deeper insights for compound screening and target validation.

4. Identification of alternative promoter usage with Total DRUG-seq

MERCURIUS™ Total DRUG-seq reveals differential promoter usage in response to TGFB treatment: HNF4A promoter 1 (P1)is inhibited, while promoter 2 (P2) is activated. This switch in promoter activity is a hallmark of epithelial-to-mesenchymal transition and is associated with tumor progression. Activation of HNF4A P2 is a known marker of hepatocarcinoma progression, highlighting the power of Total DRUG-seq to resolve complex transcriptional regulation at the promoter level.

Product specifications

Validated cell lines

Pre-order now

Be among the first to access our new MERCURIUS™ Total DRUG-seq library prep kits. Subscribe now and we will notify you the moment we are ready to ship the first kits.

PRE-ORDER or LEARN MORE

Cells and organoids (Extraction-free)

SINGLE-CELLS

Purified RNA

Accessories

Cells and Organoids (EXTRACTION-FREE)

Single-cells

PURIFIED RNA

MERCURIUS™
DRUG-seq

MERCURIUS™
FLASH-seq

MERCURIUS™
BRB-seq